We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis

By LabMedica International staff writers
Posted on 19 Jun 2026

Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. More...

For immunotherapy evaluation, the precise sequence of cell contact, activation, and later tumor-cell death can be decisive, but is rarely captured in standard workflows. Single-cell, time-based readouts remain challenging in many laboratories. Researchers now present an instrument-free lab-on-a-chip approach that visualizes immune–cancer cell interactions over time in high detail.

At the Technical University of Munich (TUM), investigators developed CellTrap, a microfluidic lab-on-a-chip platform designed to study discrete cell-to-cell contacts. The device features a large main channel that branches into 1,024 trapping chambers, where individual immune cells and cancer cells can be co-localized and immobilized. These interactions are then tracked by time-lapse microscopy for up to 14 hours, enabling continuous observation of contact formation, immune activation, and target-cell killing. The platform supports diverse experimental contexts, including cancer cells alone, immune cells alone, and varied immune-to-cancer cell ratios, while operating on a standard fluorescence microscope without specialized equipment.

Initial experiments using a glioblastoma cell line showed that tumor cells were attacked more frequently and intensely when several immune cells encountered a single target. The observations also indicated that early activation signals in immune cells often foreshadowed later cell-damaging effects, linking initiation events to outcomes within the same interaction. Beyond glioblastoma, CellTrap was tested with two additional cancer cell lines, chronic myeloid leukemia and adenocarcinoma, demonstrating applicability across different tumor contexts.

Details of the work are published in RSC Advances on April 10, 2026, under the title “CellTrap: an instrument-free microfluidic platform for cell–cell interactions at stochastically generated effector-to-target ratios.” The authors highlight that the approach enables direct visualization of how early cellular responses relate to later consequences in individual pairings, information that is typically inaccessible in bulk assays. The platform’s design emphasizes simplicity and affordability by leveraging existing fluorescence microscopy infrastructure commonly available in research labs.

“With CellTrap, we can not only measure whether immune cells kill cancer cells, but also track when and under what conditions this occurs. This matters, because immune responses can vary so much from one cell to the next. And we deliberately kept the platform simple and affordable: it runs on a standard fluorescence microscope of the kind most labs already have, with no specialised equipment,” said Ghulam Destgeer, Professor of Control and Manipulation of Microscale Living Objects at the TUM School of Computation, Information and Technology.

“The more we learn about what actually happens between individual cells, the better we can compare treatment strategies and develop new ones. And although we focused on immune and cancer cells, the platform isn’t limited to them — almost any combination of cells can be loaded and observed in the chip,” said Destgeer.

Related Links
TUM


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Molecular Diagnostics

view channel
Image: The Fast PCR System delivers sample‑to‑answer results for key pathogens in under 10 minutes (Photo courtesy of Autonomous Medical Devices Incorporated)

Point-of-Care PCR Panel Detects RSV, Influenza, and SARS-CoV-2 in Minutes

Respiratory syncytial virus, influenza, and SARS-CoV-2 remain major respiratory pathogens in ambulatory care. RSV is a particular priority because it can cause significant disease in infants, older adults,... Read more

Microbiology

view channel
Image: Burkholderia pseudomallei is a soil-dwelling bacterium that causes melioidosis, a severe and potentially fatal infection that remains difficult to diagnose (Image Credit: Gavin Koh/Wikimedia Commons, CC BY-SA 4.0)

Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread

Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.